Boosting Next-Gen Mental Health Care: Enveric's New US Patent For Anxiety Treatment
Portfolio Pulse from Lara Goldstein
Enveric Biosciences (NASDAQ:ENVB) has been granted a US patent for its lead candidate EB-373, a psilocin prodrug under development for the treatment of anxiety disorder. The patent covers compositions and methods for tryptamine-derived prodrugs. The company believes these enhancements could provide a more rapid onset of action and reduced side effects compared to traditional psilocin prodrugs. Enveric is also advancing EVM201 and EVM301 series towards creating innovative alterations to related compounds for treating critical mental health disorders.
August 28, 2023 | 8:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Enveric Biosciences has received a US patent for its lead candidate EB-373, a treatment for anxiety disorder. This could strengthen the company's IP rights and potentially lead to more patents in the future.
The granting of a patent for Enveric's lead candidate EB-373 strengthens the company's intellectual property rights and could potentially lead to more patents in the future. This could positively impact the company's stock as it demonstrates progress in their product development and potential for future growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100